Publications by HELICOVAXOR® consortium members

Throughout the course of the HELICOVAXOR® project, members of the consortium have continued to raise awareness of the potential for an oral, adjuvanted Helicobacter pylori vaccine through presentations and publications at international conferences and in scientific journals.  A list of publications is provided below:...

Read More »


Final Report Submitted to European Commission

In March 2015, the final report on the HELICOVAXOR® project was submitted to European Commission. While the work planned under the grant has been completed, the very promising results were not sufficient to justify moving to human clinical testing. A number of the consortium members continue to work together to ...

Read More »


Initial Programme of Work Broadly Complete

The initial activities of the consortium working on HELICOVAXOR® project funded under the European Community’s Seventh Framework Programme grant agreement number 315640 are mostly complete.  The consortium members are reviewing the data and planning next steps....

Read More »


July 2013 Mid Term Progress Meeting

July 19, 2013.  All participants involved in the HELICOVAXOR consortium participated in a review of progress to date and planning for future activities and deliverables.  The formal Mid-Term Review with the European Commission Research Executive Agency (REA) will take place in Brussels on September 30th, 2013.  Al...

Read More »


EHSG Annual Meeting September 2013

The XXVIth International Workshop on Helicobacter and related bacteria in chronic digestive inflammation organised by the European Helicobacter Study Group will take place in Madrid, Spain, September 12-14, 2013. Details are available on the website http://www.helicobacter.org/2013/invitation.htm  ...

Read More »


SmPill® Technology

SmPill® technology permits the controlled release of a wide range of drugs, including biopharmaceuticals, that are often optimally formulated in liquid or emulsion form for oral delivery. The industry challenges addressed by SmPill® include, but are not limited to: Poor aqueous drug solubility Poor drug abso...

Read More »


Introducing HELICOVAXOR™

In 2011, Sigmoid Pharma convened a consortium of leading researchers, agencies and companies in the field of vaccine development.  Sigmoid submitted a grant application and successfully won funding to lead this international consortium to research and develop an oral vaccine against the common gastrointestinal pathoge...

Read More »